{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:08:47Z","timestamp":1761808127384},"reference-count":113,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.rmr.2016.12.001","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T06:15:35Z","timestamp":1499840135000},"page":"618-634","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Traitements p\u00e9ri-op\u00e9ratoires des carcinomes bronchiques non \u00e0 petites cellules"],"prefix":"10.1016","volume":"34","author":[{"given":"S.","family":"Brosseau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Naltet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nguenang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Gounant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mordant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Milleron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Castier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2016.12.001_bib0570","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the TNM Stage groupings in the forthcoming (Eighth) Edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0575","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in NSCLC: a meta-analysis using updated data on individual patients from 52\u00a0randomised clinical trials","volume":"311","author":"NSCLC Collaborative Group","year":"1995","journal-title":"Br Med J"},{"key":"10.1016\/j.rmr.2016.12.001_bib0580","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199401203300301","article-title":"A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer","volume":"330","author":"Rosell","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.12.001_bib0585","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/jnci\/86.9.673","article-title":"A randomized trial comparing perioperative chemotherapy and surgery alone in resectable stage IIIA non small-cell lung cancer","volume":"86","author":"Roth","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.rmr.2016.12.001_bib0590","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jtcvs.2011.09.002","article-title":"An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer","volume":"143","author":"Kim","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.rmr.2016.12.001_bib0595","first-page":"845","article-title":"Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: a meta-analysis and system review","volume":"9","author":"Xu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.rmr.2016.12.001_bib0600","first-page":"611","article-title":"A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer","volume":"1","author":"Burdett","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0605","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.lungcan.2005.01.002","article-title":"Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature","volume":"49","author":"Berghmans","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2016.12.001_bib0610","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.2009.27.6204","article-title":"Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer","volume":"28","author":"Felip","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0615","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.ejca.2013.04.013","article-title":"A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002\u00a0trial)","volume":"49","author":"Westeel","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rmr.2016.12.001_bib0620","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3\u00a0cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0625","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1158\/1078-0432.CCR-11-1080","article-title":"Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2016.12.001_bib0630","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2147\/OTT.S93823","article-title":"Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.rmr.2016.12.001_bib0635","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejcts.2004.03.041","article-title":"Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial","volume":"26","author":"Waller","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.rmr.2016.12.001_bib0640","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jnci\/djg059","article-title":"Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer","volume":"95","author":"Scagliotti","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.rmr.2016.12.001_bib0645","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer","volume":"350","author":"The International Adjuvant Lung Cancer Trial Collaborative Group","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.12.001_bib0650","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/JCO.2009.23.2272","article-title":"Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer","volume":"28","author":"Arriagada","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0655","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0660","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ijrobp.2008.01.044","volume":"72","author":"Douillard","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rmr.2016.12.001_bib0665","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa032792","article-title":"A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung","volume":"350","author":"Kato","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.12.001_bib0670","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1200\/JCO.2005.09.017","article-title":"Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer","volume":"23","author":"Hamada","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0675","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/JTO.0b013e3181bbf1f2","article-title":"Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials","volume":"4","author":"Hamada","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0680","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1200\/JCO.2008.16.4855","article-title":"Adjuvant Paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633\u00a0with the cancer and leukemia group B. Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups","volume":"26","author":"Strauss","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0685","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22938","article-title":"Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,702\u00a0stage I patients in the California Cancer Registry from 1989\u00a0to 2003","volume":"110","author":"Ou","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.rmr.2016.12.001_bib0690","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/JTO.0b013e31807a2f81","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer","volume":"2","author":"Rami-Porta","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0695","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1002\/cncr.29045","article-title":"Analysis of stage and clinical\/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system","volume":"120","author":"Chen","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.rmr.2016.12.001_bib0700","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1164\/rccm.200706-815OC","article-title":"Survival after surgery in stage IA and IB non-small cell lung cancer","volume":"177","author":"Ost","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.12.001_bib0705","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.12.001_bib0710","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0715","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/icvts\/ivv050","article-title":"A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective","volume":"20","author":"Barlesi","year":"2015","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.rmr.2016.12.001_bib0720","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jtho.2015.09.014","article-title":"three-year follow-up of a randomized phase II Trial on refinement of early-stage NSCLC Adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine (the TREAT Study)","volume":"11","author":"Kreuter","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0725","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2013.53.1525","article-title":"Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801\u00a0TASTE","volume":"32","author":"Wislez","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0730","first-page":"2033","article-title":"Meta-analysis of postoperative adjuvant chemotherapy without radiotherapy in early stage non-small cell lung cancer","volume":"8","author":"Chen","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.rmr.2016.12.001_bib0735","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(10)60059-1","article-title":"Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data","volume":"375","author":"NSCLC Meta-analyses Collaborative Group","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2016.12.001_bib0740","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/IMI.0b013e3181662c6a","article-title":"Video-assisted thoracic surgery in lung cancer resection: a meta-analysis and systematic review of controlled trials","volume":"2","author":"Cheng","year":"2007","journal-title":"Innovations (Phila)"},{"key":"10.1016\/j.rmr.2016.12.001_bib0745","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(16)00173-X","article-title":"Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial","volume":"17","author":"Bendixen","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0750","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtho.2015.10.007","article-title":"Nodal upstaging is more common with thoracotomy than with VATS during lobectomy for early-stage lung cancer: an analysis from the National Cancer Data Base","volume":"11","author":"Medbery","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0755","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jtho.2015.08.002","article-title":"Prevalence, prognostic implications, and survival modulators of incompletely resected non-small cell lung cancer in the U.S. National cancer database","volume":"11","author":"Osarogiagbon","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0760","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jtho.2016.03.009","article-title":"Adjuvant chemotherapy for T3\u00a0non-small cell lung cancer with additional tumor nodules in the same lobe","volume":"11","author":"Salazar","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0765","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1097\/JTO.0b013e3181bbb284","article-title":"Peripheral direct adjacent lobe invasion non-small cell lung cancer has a similar survival to that of parietal pleural invasion T3\u00a0disease","volume":"4","author":"Yang","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0770","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/thoraxjnl-2011-200424","article-title":"Positive pre-resection pleural lavage cytology is associated with increased risk of lung cancer recurrence in patients undergoing surgical resection: a meta-analysis of 4450\u00a0patients","volume":"67","author":"Saso","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.12.001_bib0775","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jtcvs.2009.05.048","article-title":"Impact of positive pleural lavage cytology on survival in patients having lung resection for non-small-cell lung cancer: an international individual patient data meta-analysis","volume":"139","author":"Lim","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.rmr.2016.12.001_bib0780","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/icvts\/ivv098","article-title":"Efficacy of adjuvant chemotherapy for lung adenocarcinoma patients with positive pleural lavage cytology findings","volume":"21","author":"Ogawa","year":"2015","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.rmr.2016.12.001_bib0785","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1\u00a0in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.12.001_bib0790","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","article-title":"ERCC1\u00a0isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Friboulet","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.12.001_bib0795","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/annonc\/mdr033","article-title":"Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials","volume":"23","author":"Reiman","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0800","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ajpath.2010.11.029","article-title":"ERCC1\u00a0and RRM1\u00a0in the international adjuvant lung trial by automated quantitative in situ analysis","volume":"178","author":"Bepler","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0805","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO.2012.48.1390","article-title":"Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy","volume":"31","author":"Shepherd","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0810","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/1078-0432.CCR-09-2204","article-title":"MutS homologue 2\u00a0and the long-term benefit of adjuvant chemotherapy in lung cancer","volume":"16","author":"Kamal","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2016.12.001_bib0815","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1158\/1078-0432.CCR-06-2446","article-title":"Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program","volume":"13","author":"Filipits","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2016.12.001_bib0820","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2016.02.002","article-title":"Prognostic and Predictive effect of TP53\u00a0mutations in patients with non-small cell lung cancer from adjuvant cisplatin-based therapy randomized trials: A LACE-Bio pooled analysis","volume":"11","author":"Ma","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0825","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.2015.63.0970","article-title":"Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer","volume":"34","author":"Brambilla","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0830","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.2014.58.8335","article-title":"Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection","volume":"33","author":"Tsao","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0835","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.2006.08.2867","article-title":"Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program","volume":"25","author":"Filipits","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0840","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2009.26.4325","article-title":"Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer","volume":"28","author":"Zhu","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0845","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1158\/1078-0432.CCR-14-2206","article-title":"NRF2\u00a0pathway activation and adjuvant chemotherapy benefit in lung squamous cell carcinoma","volume":"21","author":"Cescon","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2016.12.001_bib0850","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13019-016-0427-x","article-title":"Lymph node micrometastases are associated with disease recurrence and poor survival for early-stage non-small cell lung cancer patients: a meta-analysis","volume":"11","author":"Deng","year":"2016","journal-title":"J Cardiothorac Surg"},{"key":"10.1016\/j.rmr.2016.12.001_bib0855","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/CCO.0b013e3283412eca","article-title":"Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer","volume":"23","author":"Zalcman","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0860","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1158\/1535-7163.MCT-11-0899","article-title":"High TUBB3\u00a0expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway","volume":"11","author":"Levallet","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.rmr.2016.12.001_bib0865","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1158\/1078-0432.CCR-11-2797","article-title":"An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002\u00a0trial","volume":"18","author":"de Fraipont","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2016.12.001_bib0870","first-page":"247","article-title":"Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer","volume":"20","author":"Depierre","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0875","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1200\/jco.2010.28.15_suppl.7003","article-title":"Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer","volume":"28","author":"Westeel","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0880","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(07)60714-4","article-title":"Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22\/NVALT 2\/EORTC 08012\u00a0multicentre randomised trial and update of systematic review","volume":"369","author":"Gilligan","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2016.12.001_bib0885","first-page":"656s","article-title":"Scandinavian phase III trial of neoadjuvant chemotherapy in NSCLC stages IB-IIIA\/T3 (Abstract)","author":"Sorensen","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0890","first-page":"399S","article-title":"A phase III Randomized study of surgery alone or surgery plus perioperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of Ch.E.S.T (Abstract)","author":"Scagliotti","year":"2008","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0895","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2009.26.1685","article-title":"Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial","volume":"28","author":"Pisters","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0900","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/JTO.0b013e3181cd3345","article-title":"Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13\u00a0randomized control trials","volume":"5","author":"Song","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0905","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data","volume":"383","author":"NSCLC Meta-analysis Collaborative Group","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2016.12.001_bib0910","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/JTO.0b013e31824c7d92","article-title":"Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials","volume":"7","author":"Mouillet","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0915","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0920","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtho.2015.12.104","article-title":"Adaptive neoadjuvant chemotherapy guided by 18F-FDG PET in resectable non\u2013small cell lung cancers: The NEOSCAN Trial","volume":"11","author":"Chaft","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0925","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1158\/0008-5472.CAN-15-1008","article-title":"RASSF1A suppresses the invasion and metastatic potential of human non-small cell lung cancer cells by inhibiting YAP activation through the GEF-H1\/RhoB Pathway","volume":"76","author":"Dubois","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.rmr.2016.12.001_bib0930","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1200\/jco.2011.29.15_suppl.7007","article-title":"A three-microRNAs signature accurately discriminates three prognostic groups in early-stage NSCLC patients in the IFCT-0002\u00a0trial (Abstract)","volume":"29","author":"Mascaux","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0935","doi-asserted-by":"crossref","first-page":"29761","DOI":"10.18632\/oncotarget.8858","article-title":"Genetic changes of non-small cell lung cancer under neoadjuvant therapy","volume":"7","author":"Warth","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.rmr.2016.12.001_bib0940","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1200\/JCO.2011.40.1315","article-title":"Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406\u00a0trial","volume":"30","author":"Janne","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0945","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.2011.39.4882","article-title":"Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer","volume":"30","author":"Schaake","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0950","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.1200\/JCO.2009.22.3370","article-title":"Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer","volume":"27","author":"Lara-Guerra","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0955","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-015-0151-3","article-title":"Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2\u00a0non-small cell lung cancer based on epidermal growth factor receptor mutation status","volume":"8","author":"Zhong","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0960","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1245\/s10434-014-3791-6","article-title":"(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer","volume":"21","author":"van Gool","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0965","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2011.10.020","article-title":"Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer","volume":"76","author":"Lara-Guerra","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2016.12.001_bib0970","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1200\/JCO.2013.51.1816","article-title":"Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19\u00a0study","volume":"31","author":"Goss","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0975","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial","volume":"33","author":"Kelly","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0980","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1245\/s10434-014-3586-9","article-title":"Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2\u00a0non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study","volume":"21","author":"Li","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0985","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.cllc.2015.04.002","article-title":"A retrospective study of stage I to IIIa lung adenocarcinoma after resection: what is the optimal adjuvant modality for patients with an EGFR mutation?","volume":"16","author":"Lv","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.rmr.2016.12.001_bib0990","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/JTO.0b013e31826bb7b2","article-title":"Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118\u00a0surgical specimens and effects of adjuvant gefitinib and erlotinib","volume":"7","author":"D\u2019Angelo","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0995","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.chest.2015.12.017","article-title":"Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small-cell lung cancer by a meta-analysis","volume":"149","author":"Huang","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.12.001_bib1000","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1\u00a0immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib1005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.12.001_bib1010","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.12.001_bib1015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(98)06341-7","article-title":"Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials","volume":"352","author":"PORT Meta-analysis Trialists Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2016.12.001_bib1020","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/cncr.22845","article-title":"The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database","volume":"110","author":"Lally","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.rmr.2016.12.001_bib1025","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1200\/JCO.2005.04.6110","article-title":"Postoperative radiotherapy for stage II or III NSCLC using the surveillance, epidemiology, and end results database","volume":"24","author":"Lally","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib1030","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2014.58.5380","article-title":"Postoperative radiotherapy for pathologic N2\u00a0non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base","volume":"33","author":"Robinson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib1035","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2147\/OTT.S100965","article-title":"The predictive and prognostic values of factors associated with visceral pleural involvement in resected lung adenocarcinomas","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.rmr.2016.12.001_bib1040","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1378\/chest.10-3279","article-title":"Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification","volume":"140","author":"Maeda","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.12.001_bib1045","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/JTO.0b013e31828632b8","article-title":"Visceral pleural invasion classification in non-small-cell lung cancer in the 7th edition of the tumor, node, metastasis classification for lung cancer: validation analysis based on a large-scale nationwide database","volume":"8","author":"Kawase","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib1050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0360-3016(99)00148-0","article-title":"Patterns of failure and overall survival in patients with completely resected T3\u00a0N0\u00a0M0\u00a0non-small cell lung cancer","volume":"45","author":"Gould","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rmr.2016.12.001_bib1055","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1067\/mtc.2001.112826","article-title":"Chest wall invasion in non-small cell lung carcinoma: a rationale for en bloc resection","volume":"121","author":"Facciolo","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.rmr.2016.12.001_bib1060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3857\/roj.2015.33.2.75","article-title":"Multi-institutional analysis of T3\u00a0subtypes and adjuvant radiotherapy effects in resected T3N0\u00a0non-small cell lung cancer patients","volume":"33","author":"Choi","year":"2015","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.rmr.2016.12.001_bib1065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2016.12.001_bib1070","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/icvts\/ivu378","article-title":"Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio","volume":"20","author":"Renaud","year":"2015","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.rmr.2016.12.001_bib1075","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/JTO.0b013e318292c53e","article-title":"Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer","volume":"8","author":"Urban","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib1080","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12885-015-1389-4","article-title":"Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors","volume":"15","author":"Pottgen","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.rmr.2016.12.001_bib1085","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2016.03.016","article-title":"Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2\u00a0disease","volume":"96","author":"Kim","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2016.12.001_bib1090","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(08)70156-6","article-title":"Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer","volume":"9","author":"Thomas","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib1095","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2\u00a0non-small-cell lung cancer: a phase 3\u00a0randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2016.12.001_bib1100","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.athoracsur.2012.03.018","article-title":"Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer","volume":"93","author":"Shah","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.rmr.2016.12.001_bib1105","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1002\/cncr.26585","article-title":"Postoperative radiotherapy for elderly patients with stage III lung cancer","volume":"118","author":"Wisnivesky","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.rmr.2016.12.001_bib1110","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/annonc\/mdv008","article-title":"Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer\u22654cm in size: an SEER-Medicare analysis","volume":"26","author":"Malhotra","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib1115","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1245\/s10434-014-4056-0","article-title":"Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) Non-small cell lung cancer in elderly patients","volume":"22","author":"Berry","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib1120","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1002\/cncr.29360","article-title":"Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer","volume":"121","author":"Ganti","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.rmr.2016.12.001_bib1125","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2006.09.5570","article-title":"Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10","volume":"25","author":"Pepe","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2016.12.001_bib0565","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1200\/JCO.2008.16.2727","article-title":"Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer","volume":"26","author":"Fruh","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842517300530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842517300530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T08:21:18Z","timestamp":1535617278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842517300530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":113,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0761842517300530"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2016.12.001","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitements p\u00e9ri-op\u00e9ratoires des carcinomes bronchiques non \u00e0 petites cellules","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}